AVITA Medical, Inc. (RCEL) Stock Price & Analysis
AVITA Medical, Inc. (RCEL) closed at USD 16.5 on Wednesday, October 28, 2026, up 2.61% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 16.08; the Oct 28, 2026 session ranged USD 15.68–16.68 on volume of 458,846 shares. Market capitalization is $510.29M, with a 52-week range of USD 3.22–16.68 (NCM). Source: Nexqual, retrieved October 29, 2026 at 07:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RCEL.md
Key facts (RCEL)
- Last four reported quarters (through Jun 30, 2026): revenue $75.6M, net income -$43.1M (-57.0% margin), free cash flow -$24.6M (SEC filings).
- Insider open-market purchases, last ~7 months: 6 Form 4 filings, $206K; 2 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 13.59 (range 11.78–15.18).
- Total return with dividends: 1Y +347.1% vs S&P 500 +13.6%; 5Y +0.2% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.29, revenue estimate $32.1M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RCEL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $29.2M | $34.4M | $50.1M | $64.3M | $71.6M | $75.6M |
| Gross profit | $23.3M | $28.4M | $42.4M | $55.2M | $58.8M | — |
| Operating income | -$26.5M | -$27.5M | -$42.7M | -$56.6M | -$42.5M | -$35.2M |
| Net income | -$26.6M | -$26.7M | -$35.4M | -$61.8M | -$48.6M | -$43.1M |
| EPS (diluted) | $1.17 | $1.07 | -$1.40 | -$2.39 | -$1.74 | — |
| Free cash flow | -$26.8M | -$19.5M | -$39.4M | -$58.1M | -$32.2M | -$24.6M |
| Gross margin | 79.6% | 82.4% | 84.5% | 85.8% | 82.1% | — |
| Operating margin | -90.8% | -79.9% | -85.1% | -88.1% | -59.4% | -46.6% |
| Net margin | -90.9% | -77.5% | -70.6% | -96.3% | -67.8% | -57.0% |
| Revenue growth | +104.9% | — | +45.7% | +28.1% | +11.5% | — |
| Cash + short-term investments | $111M | $79.3M | $89.1M | $35.9M | $18.2M | — |
| Total debt | — | — | $39.8M | $42.2M | $43.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (RCEL)
P/S 6.8x · FCF yield -4.82% · Earnings yield -8.44%
Insider purchases (SEC Form 4, open-market, last ~7 months) (RCEL)
6 purchases, $206K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-09 | Woody Joseph Fralin | Director | 5,200 | $21K | 4 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-09 | Woody Joseph Fralin | Director | 10,000 | $42K | 4.19 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-03 | Woody Joseph Fralin | Director | 10,000 | $41K | 4.09 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01…2026-06-02 | Woody Joseph Fralin | Director | 20,000 | $85K | 4.25 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-20 | O'Toole David D | CFO | 2,000 | $9K | 4.26 | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-19 | O'Toole David D | CFO | 2,000 | $8K | 4.24 | Opportunistic (traded every year 2023–2025, no repeating month) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (RCEL)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 13.59 (low 11.78, high 15.18).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | BTIG | Target raised | Buy | $11 → $15 |
| 2026-08-28 | Lake Street | Target raised | Buy | $8 → $12 |
| 2026-08-19 | TD Cowen | Target raised | Buy | $12 → $14 |
| 2026-08-19 | BTIG | Target raised | Buy | $7 → $11 |
| 2026-08-07 | BTIG | Upgrade | Neutral → Buy | $7 |
Total return (dividends reinvested) (RCEL)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +347.1% | +0.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +349.5% | +0.0% |
| Volatility (annualized) | 84.8% | 84.1% |
| Max drawdown | -32.6% (Feb 2026→Mar 2026) | -83.7% (Jul 2023→Jan 2026) |
RCEL earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.36 | −$0.39 | Beat +7.7% | — |
| — | Quarter ended Mar 31, 2026 | −$0.48 | −$0.38 | Miss −26.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.54 | −$0.55 | Beat +1.8% | — |
| — | Quarter ended Sep 30, 2025 | −$0.71 | −$0.46 | Miss −54.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
RCEL recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 11, 2026 | 8-K | Entered a material agreement “On August 5, 2026, the Company and Stedical Scientific, Inc. ("Stedical") entered into a Global Amendment of their existing distribution agreement and manufacturing agreement (the "Global Amendment"). Under the terms of the Global Amendment, in exchange for a $500,000 fee the Company will hold the right of first offer and refusal to expand its exclusive distribution territory to include all or a portion of the European Union, the United Kingdom, and/or Australia. In addition, the Company's share of revenue from…” |
| Aug 6, 2026 | 8-K/A | Shareholder vote results |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
RCEL revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $20.8M | 96.1% | +16.5% |
| Japan | $387,000 | 1.8% | -9.4% |
| Australia | $194,000 | 0.9% | +385.0% |
| European Union | $182,000 | 0.8% | — |
| United Kingdom | $93,000 | 0.4% | +69.1% |
| Total revenue | $21.7M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
RCEL suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Stedical Scientific | “In addition, in the United States, we hold the rights to manufacture and exclusively market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, under the terms of exclusive multi-year distribution and contract manufacturing agreements with Stedical Scientific, Inc. ("Stedical").” |
| Partner | Collagen Matrix | “In July 2024, we entered into an exclusive multi-year development and distribution agreement with Collagen Matrix, LLC d/b/a as Regenity Biosciences ("Regenity"), granting us exclusive rights to market, sell, and distribute Cohealyx, an AVITA-medical branded collagen-based dermal matrix in the U.S., with potential expansion into the European Union ("E.U."), Australia, and Japan.” |
| Partner | OrbiMed Advisors | “We had previously entered into a credit agreement with OrbiMed Advisors, LLC (as amended, the "Previous Credit Agreement") on October 18, 2023, most recently amended in the Previous Credit Agreement's Sixth Amendment, on November 5, 2025 (the "Sixth Amendment") and incurred $40.0 million of indebtedness secured by substantially all of our assets.” |
Quoted from the company's 10-K filed Feb 12, 2026.
RCEL customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 10% of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name it.
RCEL company outlook (results filed Aug 6, 2026)
- “Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc.”
Quoted word-for-word from the SEC 8-K results press release.
RCEL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.29 | $-0.35 | +$0.06 | $32.1M | 4 |
| Next quarter (ends Dec 2026) | $-0.24 | $-0.30 | +$0.06 | $34.5M | 4 |
| Current fiscal year (ends Dec 2026) | $0.42 | $0.08 | +449.7% | $125.0M | 4 |
| Next fiscal year (ends Dec 2027) | $-0.60 | $-0.86 | +$0.25 | $158.5M | 4 |
Key Statistics (as of October 29, 2026 at 07:26 UTC)
| Price | USD 16.5 |
|---|---|
| Change | ▲ 2.61% (up) |
| Previous Close | USD 16.08 |
| Open | USD 15.92 |
| Day Range | USD 15.68 – 16.68 |
| 52-Week Range | USD 3.22 – 16.68 |
| Volume | 458,846 shares |
| Market Cap | $510.29M |
| Exchange | NCM |
Technical Analysis (RCEL)
Nexqual's technical model rates RCEL "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 07:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 80.72 (overbought) |
| vs SMA50 | Above (USD 11.97) |
| MACD | 1.23 (positive) |
Analyst Ratings (RCEL)
Wall Street analysts rate RCEL "Buy" based on 3 analysts, with a mean price target of USD 13.59 (range USD 11.78–15.18), per Nexqual as of October 29, 2026 at 07:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 13.59 |
| High Target | USD 15.18 |
| Low Target | USD 11.78 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (RCEL)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.29 |
| Revenue Estimate | $32.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.36 vs est -0.39 ▲ beat |
| 2026-03-31 | USD -0.48 vs est -0.38 ▼ miss |
| 2025-12-31 | USD -0.54 vs est -0.55 ▲ beat |
| 2025-09-30 | USD -0.71 vs est -0.46 ▼ miss |
Source: Nexqual, October 29, 2026 at 07:26 UTC.
Financials & Fundamentals (RCEL)
| Total Revenue | $75.63M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +17.80% |
| Gross Margin | +81.56% |
| Operating Margin | -31.59% |
| Profit Margin | -56.96% |
| Current Ratio | 0.41 |
| Total Cash | $11.13M |
| Total Debt | $48.48M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$24.61M (-32.5% of revenue) |
Source: Nexqual, October 29, 2026 at 07:26 UTC.
Financial Health Score (RCEL)
Nexqual rates AVITA Medical, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:26 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 82%, operating -47% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Mixed — $18M cash and investments vs $43M debt (Dec 2025, SEC) |
| Cash Flow | Weak — FCF negative: -$25M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -90.2% (last 4 quarters, SEC) |
Ownership (RCEL)
| Insider Ownership | +1.52% |
|---|---|
| Institutional Ownership | +16.32% |
| Shares Outstanding | 30.93M |
| Float | 30.46M |
| Short % of Float | +9.26% |
Source: Nexqual, October 29, 2026 at 07:26 UTC.
Leadership (RCEL)
AVITA Medical, Inc. is led by Cary G. Vance, President, CEO & Executive Director, per Nexqual as of October 29, 2026 at 07:26 UTC.
| President, CEO & Executive Director | Cary G. Vance |
|---|---|
| Chief Financial Officer | David O'Toole |
| Senior Vice President of Global Operations | Niraj Doshi J.D., P.M.P. |
| Senior Vice President of Scientific & Medical Affairs | Katie Bush |
| Vice President of Investor Relations & Corporate Communications | Ben Atkins |
Major Backers & Investors (RCEL)
Notable institutional backers of AVITA Medical, Inc. include Marshall Wace LLP, AQR Capital Management, LLC, Fidelity, according to Nexqual as of October 29, 2026 at 07:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Marshall Wace LLP | 1.1% |
| AQR Capital Management, LLC | 1.04% |
| Fidelity | 0.87% |
| Morgan Stanley | 0.65% |
| NewEdge Advisors, LLC | 0.48% |
| Macquarie Group Limited | 0.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.92% |
| BlackRock | 1.84% |
| Geode Capital | 1.1% |
| State Street | 0.42% |
Source: Nexqual, October 29, 2026 at 07:26 UTC.
From AVITA Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our commercial success also depends in part on our ability to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
Partnerships
- In July 2024, we entered into an exclusive multi-year development and distribution agreement with Collagen Matrix, LLC d/b/a as Regenity Biosciences ("Regenity"), granting us exclusive rights to market, sell, and distribute Cohealyx, an AVITA-medical branded collagen-based dermal matrix in the U.S., with potential expansion into the European Union ("E.U."), Australia, and Japan.
- In January 2024, we entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. ("Stedical") to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix in the United States ("U.S.").
Legal & Regulatory Risks (Item 1A, quoted)
- We rely on third parties to conduct, supervise, and monitor our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain or maintain regulatory approval for or commercialize our products and our business could be substantially harmed.
- We may encounter substantial delays in further clinical studies necessary to support regulatory applications for additional commercial applications of our technology.
- Compliance with environmental, health and safety requirements is costly and, if not achieved, could result in material financial fines, costly litigation, and a material adverse impact on the business.
- We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt